ThePost,net.au
.

Poredeen Appoints ICB as Exclusive Named Patient Program Manager for HMTM# in Hong Kong and Macau

  • Written by The Post

“Making TauRx’s groundbreaking drug HMTM# accessible to patients with Alzheimer's Disease under Named Patient Program”

HONG KONG SAR / SINGAPORE - Media OutReach Neswire - 18 January 2024 - ICB Medical Ltd ("ICB"), a member of the Immuno Cure BioTech Group ("Immuno Cure"), is appointed as the exclusive Named Patient Program ("NPP") Manager, for TauRx's groundbreaking drug, Hydromethylthionine Mesylate ("HMTM#"), in Hong Kong SAR and Macau SAR ("Territories") by Poredeen Pte Ltd ("Poredeen"), a wholly owned subsidiary within the TauRx Pharmaceuticals Ltd group of companies ("TauRx").

More Articles ...

  1. Fung Wing Education Launched 'SimLife Camp' for Secondary School Interview Preparation and Secondary Student Career Planning Education, Empowering Students to Understand Themselves and Enhance Interview Performance
  2. Investment Sentiment in Greater Bay Area Picked Up in 2H 2023 as Housing Control Measures Gradually Relaxed
  3. Around 150 US Tech Entrepreneurs, Investors and Talent Explored Vast Opportunities in Hong Kong I&T Ecosystem Through HKSTP Innovation Mixer Reception
  4. BingX list Manta Network Coin as hype of Modular Blockchain, Celetia Ecosystem and Dymension catch on
  5. OnePlus Provides In-Depth Look at Its Latest Dual Cryo-Velocity VC Cooling System
  6. The Hong Kong Institution of Engineers "Hong Kong Engineers Week 2024" officially kicked off
  7. Welcome Prosperity with Eight Adorable Sanrio Characters Coin Banks in 7-Eleven’s Latest Shop & Earn Stamps Programme
  8. UPCX (UPC) token is listed on the Bitget trading platform
  9. Sanrio Characters Bring Chinese New Year Joy to 7-Eleven! Gather Good Luck & Blessings with 8 Roly Poly Lucky Coin Banks Overflowing with Fortune and Prosperity in the Year of the Dragon
  10. Cathay Pacific Elevates Inflight Dining Experience with Exclusive Collaborations